New dosing guidelines aim to prevent fever and treatment delays in cancer patients with rare blood trait
NCT ID NCT07341867
First seen Jan 14, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This study looks at whether using special dosing guidelines for people with the Duffy null blood trait can help them avoid treatment delays and dangerous fevers during chemotherapy for multiple myeloma or triple-negative breast cancer. About 90 participants will be enrolled, and researchers will compare their outcomes to those without the trait. The goal is to make standard cancer treatments safer and more effective for this group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.